Bright Minds Biosciences heads into its earnings release with a striking split: the loudest voice on the Street just turned more bullish, while short sellers have been piling in at a pace not seen in months.
The analyst story is the clearest positive catalyst this week. Piper Sandler maintained its Overweight rating and raised its price target to CAD 220 — a premium of more than 110% to Tuesday's close of CAD 103.73. That target hike, reported May 20, comes as the company filed its March 31 financials via Form 6-K. With consensus still anchored around CAD 128.60 according to aggregated coverage from late April, Piper's revised target sits well above the Street average, signalling that at least one bellwether sees the clinical pipeline as significantly underpriced. The EPS momentum score of 89 at the 90-day horizon and a 70 reading at 30 days reinforce that analyst estimate revisions have been running in a constructive direction.
Short interest tells a strikingly different story. Estimated short interest as a percentage of free float is only 0.20% — a genuinely small number — but the rate of change is eye-catching. Shares borrowed roughly tripled over the past month, up 202%, and surged 73% in a single session on May 19. The absolute position remains tiny relative to the float, so this is not a crowded short by any measure. Still, the acceleration ahead of earnings is a notable shift in tone. Cost to borrow is running at 2.27% annually — modest and largely flat on the week — and with availability at 367%, there is ample room in the lending pool for shorts to continue building if they choose. The ORTEX short score of 36.3 sits in the lower half of the range, consistent with the low-crowding read.
The institutional picture adds further texture to the ownership story. Janus Henderson is the largest declared holder at 13.1% of shares, after adding 128,000 shares through March 31. BlackRock added 228,000 shares through April 30, bringing its stake to 6.4%. On the other side, Cormorant Asset Management trimmed 109,000 shares on April 28 at CAD 89.50 — an exit priced well below Tuesday's close — and that move was followed by a small COO sell of 2,500 shares at around CAD 121, also on April 30. Vestal Point Capital and Deerfield Management each initiated fresh positions through March 31. The net read is one of rotation rather than broad exodus: specialist healthcare funds are adding while at least one longer-standing holder is trimming.
The valuation backdrop is typical of a pre-revenue clinical biotech. Both the P/E and EV/EBITDA multiples are deeply negative, reflecting ongoing losses — quarterly cash burn of roughly CAD 8.4M per the most recent results. The EV has widened notably on a one-day basis, likely capturing the post-Piper rally in market cap. The February 2026 earnings print produced a +7.7% one-day move and a +16% five-day move, the stronger of the two available historical readings. The prior print in the same period showed a more modest -1.9% one-day reaction that recovered to +9.1% over five days. Both reactions were ultimately constructive, though the sample is small.
The stock is down 8% on the week and 16% over the past month, sitting at CAD 103.73 after pulling back from a 3-month high near CAD 123.50. Among correlated peers, ARCT fell 22.5% over the week and BMEA dropped 22.3%, suggesting the broader small-cap biotech cohort has been under pressure. DRUG's 8% decline is notably shallower than its closest correlated names — a relative resilience worth noting given the sector-wide selloff.
What to watch: the earnings release filed today (May 20) will be the main event. The gap between Piper Sandler's CAD 220 target and the current price will either attract fresh buyers or test how much of the optimism is already priced into the recent momentum. The short-interest acceleration into the print is a flag — small in absolute terms, but the direction and speed of the move in borrowed shares will be worth tracking in the sessions that follow.
See the live data behind this article on ORTEX.
Open DRUG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
